Expertise in
31
conditions

Dr. Deepa Jagadeesh

Cleveland, OH
Expertise in
31
conditions
On Staff At
Specialties:Hematology | Oncology
Offers Telehealth
Expertise in
31
conditions
OverviewInsuranceLocationsClinical Research

Overview

Deepa Jagadeesh is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Jagadeesh is highly rated in 31 conditions, according to our data. Her top areas of expertise are T-Cell Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 91 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Hillcrest Hospital
Cleveland Clinic
Akron General Medical Center
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Oscar
  •  Humana

Locations

Cleveland Clinic Main Campus
9500 Euclid Avenue, Cleveland, OH 44195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Study Phase: Phase 2
Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
Enrollment Status: Approved_for_marketing
Publish Date: December 18, 2024
Intervention Type: Drug
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)
A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2024
Intervention Type: Drug, Other
Study Drug: Ibrutinib
Study Phase: Phase 2
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
Enrollment Status: Unknown
Publish Date: February 21, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Etoposide, Ixazomib Citrate, Methotrexate, Prednisone, Rituximab, Therapeutic Hydrocortisone, Vincristine Sulfate
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 13, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

95 Total Publications

Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047].
Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 03, 2024
Similar Doctors
Expertise in
30
conditions
Dr. Jaroslaw P. Maciejewski
Hematology | Oncology
Expertise in
30
conditions
Dr. Jaroslaw P. Maciejewski
Hematology | Oncology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jaroslaw Maciejewski is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Maciejewski is highly rated in 30 conditions, according to our data. His top areas of expertise are Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Splenectomy.

Expertise in
25
conditions
Dr. Anjali S. Advani
Hematology | Oncology
Expertise in
25
conditions
Dr. Anjali S. Advani
Hematology | Oncology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
Languages Spoken:
English
See accepted insurances

Anjali Advani is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Advani is highly rated in 25 conditions, according to our data. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant.

Moshe C. Ornstein
Expertise in
24
conditions
Dr. Moshe C. Ornstein
Oncology | Hematology
Expertise in
24
conditions
Dr. Moshe C. Ornstein
Oncology | Hematology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Moshe Ornstein is an Oncologist and a Hematologist in Cleveland, Ohio. Dr. Ornstein is highly rated in 24 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Gamma Knife Radiosurgery.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile